Results 81 to 90 of about 2,244,220 (290)

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Biomarkers for Huntington's disease: an update [PDF]

, 2012
Huntington's disease (HD) is a devastating autosomal-dominant neurodegenerative condition caused by a CAG repeat expansion in the gene encoding huntingtin which is characterised by progressive motor impairment, cognitive decline and neuropsychiatric ...
Scahill, RI, Tabrizi, SJ, Wild, EJ
core   +1 more source

The minor collagens in articular cartilage

Protein & Cell, 2017
Articular cartilage is a connective tissue consisting of a specialized extracellular matrix (ECM) that dominates the bulk of its wet and dry weight. Type II collagen and aggrecan are the main ECM proteins in cartilage.
Yunyun Luo, Dovile Sinkeviciute, Yi He, Morten Karsdal, Yves Henrotin, Ali Mobasheri, Patrik Önnerfjord, Anne Bay-Jensen   +7 more
doaj   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Hemostasis biomarkers and incident cognitive impairment: the REGARDS study [PDF]

, 2018
Essentials Cognitive disorders are increasing and vascular risk factors play a role in this. We performed a nested case control study of hemostasis biomarkers and cognitive impairment (CI). Higher baseline fibrinogen, factor VIII and D-dimer were related
Callas, P.W., Cushman, M., Gillett, S.R., Letter, A.J., McClure, L.A., Thacker, E.L., Unverzagt, F.W., Wadley, V.G.   +7 more
core   +1 more source

Identification and validation of tumor microenvironment-related prognostic biomarkers in breast cancer [PDF]

, 2021
Shanliang Zhong, Zhangjun Jia, Heda Zhang, Zhen Gong, Jifeng Feng, Hanzi Xu   +5 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Breast-Lesion Characterization using Textural Features of Quantitative Ultrasound Parametric Maps [PDF]

, 2017
© 2017 The Author(s). This study evaluated, for the first time, the efficacy of quantitative ultrasound (QUS) spectral parametric maps in conjunction with texture-analysis techniques to differentiate non-invasively benign versus malignant breast lesions.
A Ahmed, A Heindl, A König, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, AV Alvarenga, B Sigel, D Sengupta, E Feleppa, EJ Feleppa, EJ Feleppa, EJ Feleppa, EJ Feleppa, EJ Feleppa, F Davnall, FL Lizzi, FL Lizzi, FLL Lizzi, H Tadayyon, H Tadayyon, H Tadayyon, H Tadayyon, J Mamou, JPB O’Connor, K Polyak, KA Wear, KA Wear, KC Balaji, L Sannachi, LX Yao, M Vaidya, MJ Gerdes, ML Oelze, ML Oelze, ML Oelze, ML Oelze, ML Oelze, N Duric, N Sannomiya, R Natrajan, RJ Lavarello, RL Siegel, RM Haralick, S Chicklore, S Tan, T Cover, T Noritomi, TJ Larkin, V Goh, Y Labyed, Y Labyed, Y-Y Liao   +55 more
core   +2 more sources

Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients

Frontiers in Neuroscience, 2020
Leucine-rich repeat kinase 2 (LRRK2) mutations are among the most significant genetic risk factors for developing late onset Parkinson’s disease (PD). To understand whether a therapeutic can modulate LRRK2 levels as a potential disease modifying strategy,
Omar S. Mabrouk, Siwei Chen, Amanda L. Edwards, Minhua Yang, Warren D. Hirst, Danielle L. Graham   +5 more
doaj   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source